Abbott agrees to US$670 million settlement of infant formula cases
About 1,000 similar lawsuits have been filed against Abbott and Mead Johnson,
Add BT as a preferred source
ABBOTT said on Thursday (Aug 20) it reached a US$670 million settlement with three law firms to resolve legal claims by 2,000 people who alleged harms relating to the company’s specialty formulas for preterm infants.
The settlement includes one large case in which Abbott had already been ordered to pay US$495 million. In 2024, a jury in St. Louis found that Abbott’s infant formula caused an Illinois girl to develop necrotizing enterocolitis, a dangerous bowel disease.
Abbott had been appealing that verdict to Missouri’s Supreme Court, after a state court of appeals affirmed the judgment in May 2026.
About 1,000 similar lawsuits have been filed against Abbott, which makes Similac formulas, and Mead Johnson, a unit of Reckitt which manufactures Enfamil formulas.
More than 800 of the cases are centralised in an Illinois federal court, with others pending in state courts including Illinois, Missouri and Pennsylvania.
Necrotizing enterocolitis, which mostly affects premature newborns, causes the death of bowel tissue and has an estimated mortality rate of more than 20 per cent.
The companies have said that, while breast milk protects against the disease, their formulas do not cause it and the benefits of breast milk have long been known to clinicians. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Japan Home closing outlets; staff say Valu$ taking over operations
Timah Partners lands S$60 million facility from lenders including UOB, RHB
